Skip to content
3C Therapeutics
  • AboutExpand
    • Our Mission
    • Our Platform
    • Our Team
  • ScienceExpand
    • Targeted Protein Degradation
    • Degrader-Antibody Conjugates
    • Why TriCore
  • News & Events
  • Contact
3C Therapeutics
Media

3C Therapeutics featured in BioCentury

Byadmin May 14, 2026October 16, 2026

BioCentury’s Emerging Company Profile covers 3C’s modular approach to degrader-antibody conjugates.

Read the BioCentury profile

Post navigation

Previous Previous
Vancouver-based 3C Therapeutics to apply Variational AI’s Enki™ platform to ligand design for proprietary TriCore DAC platform under Innovate BC’s Integrated Marketplace program
NextContinue
Mitacs Accelerate supports process development for 3C Therapeutics’ DAC research
3C Therapeutics
  • About
  • Science
  • News & Events
  • Contact

© 2026 3C Therapeuticsinfo@3ctherapeutics.comLinkedIn

  • About
    • Our Mission
    • Our Platform
    • Our Team
  • Science
    • Targeted Protein Degradation
    • Degrader-Antibody Conjugates
    • Why TriCore
  • News & Events
  • Contact